Coronary stents: In these days of climate change should all stents wear coats?

Heart

Volumn 91, Issue SUPPL. 3, 2005, Pages

  Lowe, R ^a   Menown, I B A ^a   Nogareda, G ^a   Penn, I M ^a  

^a VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CARBON; CHROMIUM; COBALT; GOLD; HEPARIN; NITINOL; PHOSPHORYLCHOLINE; TANTALUM; TITANIUM;

BLOOD VESSEL REACTIVITY; CLIMATE CHANGE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; ENDOTHELIUM CELL; HUMAN; IN-STENT RESTENOSIS; MATERIAL COATING; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOGENICITY;

CARBON; CARBON COMPOUNDS, INORGANIC; CHROMIUM ALLOYS; CORONARY RESTENOSIS; HEPARIN; HUMANS; METALS; PHOSPHORYLCHOLINE; SILICON COMPOUNDS; STENTS; TANTALUM;

EID: 20044379309     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.060269     Document Type: Review

References (56)

1. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N Engl J Med 1994;331:489-95.
2. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med 1994;331:496-501.
3. Gershlick AH, Baron J. Dealing with in-stent restenosis. Heart 1998;79:319-23.
4. Liistro F, Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart 2001;86:262-4.
5. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002;106:2649-51.
6. Nakayama Y, Ji-Youn K, Nishi S, et al. Development of high-performance stent: gelatinous photogel-coated stent that permits drug delivery and gene transfer. J Biomed Mater Res 2001;57:559-66.
7. Gotman I. Characteristics of metals used in implants. J Endourol 1997;11:383-9.
8. Rothman M, Serruys P, Grollier G, et al. Angiographic and clinical one-year follow-up of the Cordis tantalum coil stent in a multicenter international study demonstrating improved restenosis rates when compared to pooled PTCA and BENESTENT-I data: the European antiplatelet stent investigation (EASI). Catheter Cardiovasc Interv 2001;52:249-59.
9. Verheye S, Salame MY, Robinson KA, et al. Short- and long-term histopathologic evaluation of stenting using a self-expanding nitinol stent in pig carotid and iliac arteries. Catheter Cardiovasc Interv 1999;48:316-23.
10. Kastrari A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001;103:2816-21.
11. Kereiakes DJ, Cox DA, Hermiller JB, et al. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 2003;92:463-6.
12. Hoffmann R, Mintz GS, Haager PK, et al. Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. Am J Cardiol 2002;89:1360-4.
13. vom Dahl J, Haager PK, Grube E, et al. Effects of gold coating of coronary stents on neointimal proliferation following stent implantation. Am J Cardiol 2002;89:801-5.
14. Kastrari A, Schomig A, Dirschinger J, et al. Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation 2000;101:2478-83.
15. Edelman ER, Seifert P, Groothuis A, et al. Gold-coated NIR stents in porcine coronary arteries. Circulation 2001;103:429-34.
16. Hehrlein C, Zimmermann M, Metz J, et al. Influence of surface texture and charge on the biocompatibility of endovascular stents. Coron Artery Dis 1995;6:581-6.
17. Tanigawa N, Sawada, S, Kobayashi M. Reaction of the aortic wall to six metallic stent materials. Acad Radiol 1995;2:379-84.
18. de Scheerder I, Verbeken E, Van Humbeeck J. Metallic surface modification. Semin Interv Cardiol 1998;3:139-44.
19. Gutensohn K, Beythien C, Bau J, et al. In vitro analyses of diamond-like carbon coated stents. Reduction of metal ion release, platelet activation, and thrombogenicity. Thromb Res 2000;99:577-85.
20. Korkmaz ME, Tayfun E, Muderrisoglu H, et al. Carbon coating of stents has no effect on inflammatory response to primary stent deployment. Angiology 2002;53:563-8.
21. de Scheerder I, Szilard M, Yanming H, et al. Evaluation of the biocompatibility of two new diamond-like stent coatings (Dylyn) in a porcine coronary stent model. J Invasive Cardiol 2000;12:389-94.
22. Bartorelli AL, Trabattoni D, Montorsi P, et al. Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent: the ANTARES study. Catheter Cardiovasc Interv 2002;55:150-6.
23. Antoniucci D, Bartorelli A, Valenti R, et al. Clinical and angiographic outcome after coronary arterial stenting with the carbostent. Am J Cardiol 2000;85:821-5.
24. Heublein B, Pethig K, Elsayed AM. Silicon carbide coating N A semiconducting hybrid design of coronary stents N A feasibility study. J Invasive Cardiol 1998;10:255-62.
25. Carrie D, Khalife K, Hamon M, et al. Initial and follow-up results of the Tenax coronary stent. J Interv Cardiol 2001;14:1-5.
26. Fournier JA, Calabuig J, Merchan A, et al. [Initial results and 6 month clinical follow-up after implantation of a silicon carbide coated coronary stent]. Rev Esp Cardiol 2001;54:567-72.
27. Ozbek C, Heisel A, Gross B, et al. Coronary implantation of silicone-carbide-coated Palmaz-Schatz stents in patients with high risk of stent thrombosis without oral anticoagulation. Cathet Cardiovasc Diagn 1997;41:71-8.
28. Hamm C. TENAX-XR a:SiC-H coated stent versus noncoated stents in 485 patients with acute coronary syndrome: 9- and 18-month follow-up: the TRUST trial. J Am Coll Cardiol 2002;39:310A.
29. Elbaz M, El Mokhtar E, Fourcade J, et al. Does stent design affect the long-term outcome after coronary stenting? Catheter Cardiovasc Interv 2002;56:305-11.
30. Cumberland DC, Gunn J, Malik N, et al. Biomimicry 1: PC. Semin Interv Cardiol 1998;3:149-50.
31. Whelan DM, van der Giessen WJ, Krabbendam SC, et al. Biocompatibilily of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000;83:338-45.
32. Kuiper KK, Robinson KA, Chronos NA, et al. Phosphorylcholine-coated metallic stents in rabbit iliac and porcine coronary arteries. Scand Cardiovasc J 1998;32:261-8.
33. Lewis AL, Furze JD, Small S, et al. Long-term stability of a coronary stent coating post-implantation. J Biomed Mater Res 2002;63:699-705.
34. Lewis AL, Tolhurst LA, Stratford PW. Analysis of a phosphorylcholine- based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 2002;23:1697-706.
35. Malik N, Gunn J, Shepherd L, et al. Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibilily. J Invasive Cardiol 2001;13:193-201.
36. Atalar E, Haznedaroglu I, Aytemir K, et al. Effects of stent coating on platelets and endothelial cells after intracoronary stent implantation. Clin Cardiol 2001;24:159-64.
37. Galli M, Bartorelli A, Bedogni F, et al. Italian BiodivYsio open registry (BiodivYsio PC-coated stent): study of clinical outcomes of the implant of a PC-coated coronary stent. J Invasive Cardiol 2000;12:452-8.
38. Beaudry Y, Sze S, Fagih B, et al. Six-month results of small vessel stenting (2.0-2.8 mm) with the Biodiv Ysio SV stent. J Invasive Cardiol 2001;13:628-31.
39. Boland JL, Corbeij HA, van der GW, et al. Multicenter evaluation of the phosphorylcholine-coated biodiv Ysio stent in short de novo coronary lesions: the SOPHOS study. Int J Cardiovasc Intervent 2000;3:215-25.
40. Grenadier E, Roguin A, Hertz I, et al. Stenting very small coronary narrowings (<2 mm) using me biocompatible phosphorylcholine-coated coronary stent. Catheter Cardiovasc Interv 2002;55:303-8.
41. McNair AM. Using hydrogel polymers for drug delivery. Med Device Technol 1996;7:16-22.
42. New G, Moses JW, Roubin GS, et al. Estrogen-eluting, phosphorylcholine- coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Catheter Cardiovasc Interv 2002;57:266-71.
43. Herrmann R, Schmidmaier G, Markl B, et al. Antithrombogenic coating of stents using a biodegradable drug delivery technology. Thromb Haemost 1999;82:51-7.
44. Alt E, Haehnel I, Beilharz C, et al. Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. Circulation 2000;101:1453-8.
45. Christensen K, Larsson R, Emanuelsson H, et al. Coagulation and complement activation. Biomaterials 2001;22:349-55.
46. Tarnok A, Mahnke A, Muller M, et al. Rapid in vitro biocompatibility assay of endovascular stents by flow cytometry using platelet activation and platelet-leukocyte aggregation. Cytometry 1999;38:30-9.
47. Bickel C, Rupprecht HJ, Darius H, et al. Substantial reduction of platelet adhesion by heparin-coated stents. J Interv Cardiol 2001;14:407-13.
48. Beythien C, Gutensohn K, Bau J, et al. Influence of stent length and heparin coating on platelet activation: a flow cytometric analysis in a pulsed floating model. Thromb Res 1999;94:79-86.
49. Blezer R, Cahalan L, Cahalan PT, et al. Heparin coating of tantalum coronary stents reduces surface thrombin generation but not factor IXa generation. Blood Coagul Fibrinolysis 1998;9:435-40.
50. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasly in selected patients with coronary artery disease (Benestent II). Lancet 1998;352:673-81.
51. Haude M, Konorza TF, Kalnins U, et al. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. Circulation 2003;107:1265-70.
52. Wohrle J, Al Khayer E, Grotzinger U, et al. Comparison of the heparin coated vs the uncoated Jostent-no influence on restenosis or clinical outcome. Eur Heart J 2001;22:1808-16.
53. Vrolix MC, Legrand VM, Reiber JH, et al. Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR trial investigators. Am J Cardiol 2000;86:385-9.
54. Fleser PS, Nuthakki VK, Malinzak LE, et al. Nitric oxide-releasing biopolymers inhibit thrombus formation in a sheep model of arteriovenous bridge grafts. J Vasc Surg 2004;40:803-11.
55. Do YS, Kao EY, Ganaha F, et al. In-stent restenosis limitation with stent-based controlled-release nitric oxide: initial results in rabbits. Radiology 2004;230:377-82.
56. Buergler JM, Tio FO, Schulz DG, et al. Use of nitric-oxide-eluting polymer-coated coronary stents for prevention of restenosis in pigs. Coron Artery Dis 2000;11:351-7.